Farallon Capital Management LLC Uni Qure N.V. Transaction History

Farallon Capital Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$35.35 - $50.67 $5.3 Million - $7.6 Million	-150,000 Reduced 33.33%	300,000 $10.8 Million
Q3 2020 Nov 16, 2020	BUY	$35.98 - $47.66 $5.4 Million - $7.15 Million	150,000 Added 50.0%	450,000 $16.6 Million
Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $2.25 Million - $3.39 Million	50,000 Added 20.0%	300,000 $13.5 Million
Q1 2020 May 15, 2020	BUY	$40.01 - $73.97 $2 Million - $3.7 Million	50,000 Added 25.0%	250,000 $11.9 Million
Q4 2019 Feb 13, 2020	BUY	$37.13 - $74.62 $3.68 Million - $7.39 Million	99,078 Added 98.17%	200,000 $14.3 Million
Q3 2019 Nov 14, 2019	BUY	$39.36 - $76.8 $36,289 - $70,809	922 Added 0.92%	100,922 $3.97 Million
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $5.28 Million - $8.22 Million	100,000 New	100,000 $7.82 Million

142

35.3M

1.54M

389K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $300M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Farallon Capital Management LLC with notifications on news.